Novo Nordisk narrowly raised its financial outlook for 2024, despite expecting profit and sales to decline for the year. The adjustment came after the company reported the fastest take-up in weight-loss drug history for its Wegovy pill.
The Danish pharmaceutical company now projects sales growth of 23% to 27% for 2024. That is up from the previous forecast of 19% to 27%. It also expects operating profit to grow by 21% to 27%, compared to an earlier estimate of 20% to 28%.
The guidance revision was modest, reflecting the company’s cautious stance. Novo Nordisk still anticipates a decrease in profit and sales from its blockbuster weight-loss drug Wegovy, once adjusted for one-time items.
The Wegovy pill, an oral version of the injectable drug, saw rapid adoption upon its launch. This marked a significant milestone in the weight-loss drug market, where demand has surged globally.
Despite the pill’s success, Novo Nordisk faces challenges. Supply constraints and manufacturing capacity issues have limited its ability to meet full demand. The company has invested heavily in expanding production.
Analysts noted that the narrow guidance lift suggests Novo Nordisk is managing expectations carefully. The company remains focused on scaling production and navigating competitive pressures from other drugmakers entering the obesity treatment space.
Novo Nordisk’s stock responded with slight gains after the announcement. Investors digested the news as a sign of cautious optimism amid ongoing supply and demand dynamics in the weight-loss drug sector.
